NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Technology Appraisal (Committee C) meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 9 February 2021

**Location:** Via Zoom

# Committee members present.

1. Professor Steve O’Brien [Chair] Present for all items
2. Dr Peter Selby [Vice Chair] Present for all items
3. Dr Alex Cale Present for all items
4. Michael Chambers Present for all items
5. Dr Prithwiraj Das Present for items 1 to 3.4.2
6. Dr David Foreman Present for all items
7. Dr Robert Forsyth Present for all items
8. Dr Natalie Hallas Present for items 1 to 4.4.2
9. John Hampson Present for all items
10. Dr Nigel Langford Present for all items
11. Dr Andrea Manca Present for all items
12. Kirandip Moyo Present for all items
13. Dr Mudasar Mushtaq Present for items 1 to 3.3
14. Dr Richard Nicholas Present for all items
15. Ugochinyere Nwulu Present for all items
16. Stella O’Brien Present for all items
17. Professor Andrew Renehan Present for all items
18. Professor Matthew Stevenson Present for all items
19. Professor Paul Tappenden Present for items 1 to 3.4.2 & 5 to 5.4.2
20. Dr Derek Ward Present for all items

# NICE staff present:

Jasdeep Hayre, Associate Director Present for items 1 to 3.4.2 & 5 to 5.4.2

Ross Dent, Associate Director Present for items 4 to 4.4.2

Gavin Kenny, Project Manager Present for items 1 to 3.4.2 & 5 to 5.4.2

Louise Jafferally, Project Manager Present for items 4 to 4.4.2

Nicola Hay, Technical Adviser Present for items 1 to 3.4.2

Chris Griffiths, Technical Adviser Present for items 1 to 3.4.2

Sally Doss, Technical Adviser Present for items 5 to 5.4.2

Alan Moore, Technical Analyst Present for items 1 to 3.4.2

Zain Hussain, Technical Analyst Present for item 4 to 4.4.2

Cameron Collins, Technical Analyst Present for items 5 to 5.4.2

Gareth Murphy, Business Analyst Present for all items

Emilene Coventry, Medical Editor Present for items 1 to 3.4.2

Olivia Havercroft, Medical Editor Present for items 4 to 5.4.2

Ella Livingstone, Commercial & Managed Access Present for items 5 to 5.4.2

Stevie Okoro, Commercial & Managed Access Present for items 4 to 4.4.2

Tom Strong, Commercial & Managed Access Present for items 4 to 4.4.2

Laura Marsden, Public Involvement Advisor, PIP Present for items 1 to 3.3

Mandy Tonkinson, Public Involvement Advisor, PIP Present for items 4 to 4.3

Catherine Pank, Assistant Project Manager, COT Present for items 1 to 3.4.2

Gemma Smith, Coordinator, COT Present for all items

Rosalee Mason, Coordinator, MIP Present for items 1 to 3.3 & 5 to 5.3

Maria Pitan, Project Manager, MIP Present for items 4 to 4.3

Ismahan Abdullah, Administrator, TA Present for items 1 to 3.4.2 & 5 to 5.4.2

Celia Mayers, Administrator, TA Present for items 4 to 4.4.2

Pratit Shah, Administrator, TA Present for items 4 to 4.4.2

Daniel Greenwood, Assistant Administrator, COT Present for items 4 to 4.3 & 5 to 5.4.2

# External group representatives present:

Jo Lord, Southampton Health Technology Assessment Centre Present for items 1 to 3.3

Jo Picot, Southampton Health Technology Assessment Centre Present for items 1 to 3.3

Irina Tikhonova, Southampton Health Technology Assessment Centre Present for items 1 to 3.3

Professor Paul Tappenden, School of Health and Related Research Present for items 4 to 4.3

Aline Nevega Biz, School of Health and Related Research Present for items 4 to 4.3

Gemma Marceniuk, BMJ Group Present for items 5 to 5.3

Victoria Wakefield, BMJ Group Present for items 5 to 5.3

# Professional experts present:

Martin Allen, Consultant Physician, University Hospital North Midlands, Present for items 1 to 3.3

Dr Sofia Eriksson, Consultant Neurologist, National Hospital for Neurology and Neurosurgery/UCLH NHS foundation Trust, Present for items 1 to 3.3

Matt O’Neil, Patient expert nominated by Narcolepsy UK, Present for items 1 to 3.3.

Helen Strongman, Patient expert nominated by Narcolepsy UK, Present for items 1 to 3.3.

Professor Anna Schuh, Associate Professor and Consultant Haematologist, University of Oxford, Present for items 4 to 4.3

Professor Adrian Bloor, Consultant Haematologist, The Christie NHS Foundation Trust, Present for items 4 to 4.3

Nick York, Patient expert nominated by Leukaemia Care, Present for items 4 to 4.3.

Jackie Martin, Patient expert nominated by CLL Support, Present for items 4 to 4.3.

Peter Clark, CDF Clinical Lead, NHS England, Present for items 4 to 4.3

1. Introduction to the meeting
	1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
	1. None
3. Appraisal of Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy [ID1602]
	1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Jazz Pharmaceuticals.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Michael Chambers declared a financial interest as he has provided consultancy advice to Shire Pharmaceuticals [manufacturer of a potential comparator therapy], in disease areas unrelated to this appraisal and most recently in late 2017. Shire is now part of Takeda Pharmaceuticals, with whom I currently have a long-term contract to undertake activities in EU Innovative Medicines Initiative [IMI] projects, again unrelated to the topic of this appraisal.
* It was agreed that his declarations would not prevent Michael from participating in this section of the meeting.
* Dr Richard Nicholas declared a financial interest as he has attended paid advisory boards for Novartis in an unrelated area.
* It was agreed that his declaration would not prevent Richard from participating in this section of the meeting.
* Matt O’Neill declared a financial interest as he has received speaker and advisory board fees from Lincoln Medical Ltd, Takeda UK & UCB Pharma UK and has received grants/honoria from Avadel, Lincoln Medical Ltd, UCB Pharma UK & Jazz Pharma Ltd. Matt confirmed all fees are all paid to Narcolepsy UK & all his time is provided on a voluntary basis only.
* It was agreed that his declaration would not prevent Matt from providing expert advice to the committee.
* Sofia Erickson declared a non-financial interest as she has received honoraria for educational activities and conference attendance from, UCB Pharma, Lincoln Pharma, Eisai and Fidia Pharma. Sofia confirmed none were received after November 2019.
* It was agreed that her declaration would not prevent Sofia from providing expert advice to the committee.
* Helen Strongman declared non-financial interests as she is Trustee at Narcolepsy UK and Assistant Professor at the London School of Hygiene & Tropical Medicine.
* It was agreed that her declaration would not prevent Helen from providing expert advice to the committee.
* No further conflicts of interest were declared for this topic.
	1. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
	2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
	3. Part 2– Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting]
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD]. The committee decision was reached through a vote by members.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] in line with their decisions.

1. Appraisal of Acalabrutinib for untreated and treated chronic lymphocytic leukaemia [ID1613]
	1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from AstraZeneca.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Michael Chambers declared a financial interest as he has recently been co-ordinating a training programme for Roche pharmaceuticals in Real World Evidence, but this has not involved specific consideration of any Roche medicines.
* It was agreed that his declarations would not prevent Michael from participating in this section of the meeting.
* Dr Richard Nicholas declared a financial interest as he has attended paid advisory boards for Novartis in an unrelated area.
* It was agreed that his declaration would not prevent Richard from participating in this section of the meeting.
* Professor Matt Stevenson declared a non-financial interest as ScHARR-TAG was the ERG and he is the director of ScHARR-TAG. Matt confirmed he was not involved in the work on this topic.
* It was agreed that his declaration would not prevent Matt from participating in this section of the meeting.
* Professor Adrian Bloor declared financial interests as he has attended Advisory Boards and received conference funding and speaker fees for Novartis, Gilead, Abbvie and Janssen in the last five years. Adrian is also Medical Lead for The Doctors Laboratory Manchester Hub.
* It was agreed that his declaration would not prevent Adrian from providing expert advice to the committee.
* Professor Anna Schuh declared financial interests as she received honoraria for giving education talks from Abbvie, Roche, Janssen, Gilead in the last two years. Anna is also a PI on the Abbvie study M13-982 which was the study evaluating venetoclax in patients with del17 CLL.
* It was agreed that her declaration would not prevent Anna from providing expert advice to the committee.
* Nick York declared financial interests as an employee of Leukaemia Care and Chair of the CLL Advocates Network [CLLAN], which receives funding from pharmaceutical companies.
* It was agreed that his declaration would not prevent Nick from providing expert advice to the committee.
* No further conflicts of interest were declared for this item.
	1. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] or Final Appraisal Document [FAD] received from consultees, commentators and through the NICE website.
	2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
	3. Part 2 – Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting].
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD]. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] in line with their decisions.
1. Appraisal of Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]
	1. Part 1 – Open session
		1. The chair welcomed the invited, external group representatives, members of the public and company representatives from Daiichi Sankyo UK Ltd.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Richard Nicholas declared a financial interest as he has attended paid advisory boards for Novartis in an unrelated area.
* It was agreed that his declaration would not prevent Richard from participating in this section of the meeting.
* No further conflicts of interest were declared for this item.
	1. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] or Final Appraisal Document [FAD] received from consultees, commentators and through the NICE website.
	2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
	3. Part 2 – Closed session [company representatives, external group representatives and members of the public were asked to leave the meeting].
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD]. The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] in line with their decisions.
1. Date of the next meeting

The next meeting of the Technology Appraisal (Committee C) will be held on Wednesday 10 March 2021 and will start promptly at 09.30am.